1.02
1.02 (0.71%)
As of Oct 12, 2022
Theriva Biologics, Inc. [SYN]
Source:
Company Overview
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need.
| Country | United States |
| Headquarters | rockville, maryland |
| Phone Number | (734) 332-7800 |
| Industry | manufacturing |
| CEO | Steven A. Shallcross |
| Website | www.therivabio.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-26.3 |
| Net Income | $-25.7 |
| Net Cash | $-11.6 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -56.7% |
| Profit as % of Stockholder Equity | -134.5% |
Management Effectiveness
| Return on Equity | -134.5% |
| Return on Assets | -72.6% |
| Turnover Ratio | |
| EBITA | $-26.3 |
Balance Sheet and Cash Flow Measures
| Total Assets | $35.4 |
| Total Liabilities | $16.3 |
| Operating Cash Flow | $-16.9 |
| Investing Cash Flow | $-0 |
| Financing Cash Flow | $5.5 |
